Stay updated with breaking news from Recommended Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from https://immatics.com/, Immatics Announces Full Year 2021 Financial Results and Corporate Update
IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor types in an interim update of Phase 1a dose escalationMultiple IMA203 Phase
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...